Clinical Trial

Comparison of Radiographic Fusion Rate and Clinical Outcome of ALIF and XLIF Performed With Either Recombinant Human Bone Morphogenetic Protein-2 or ViviGen®

Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to prospectively investigate the potential for bony fusion of ViviGen® bone graft substitute in comparison to rhBMP-2 in monosegmental ALIF procedure L5/S1 and in monosegmental XLIF procedure L4/5
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-02-03; most recent amendment 2025-06-04.
Status change: Not Yet Recruiting → Recruiting 2022-10-27
Trial Details
NCT Number NCT05238740
Lead Sponsor Lindenhofgruppe AG
Conditions Spondylosis, Spondylolisthesis, Degenerative Disc Disease
Enrollment 168 participants
Start Date 2022-10-27
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-06-08